We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Xspray Pharma AB announces positive data from a clinical bioequivalence study with the company's lead product candidate HyNap-Dasa. The study results confirmed its primary aim to show bioequivalence of an optimized formulation of HyNap-Dasa compared to Sp